Compare CDZIP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZIP | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 191.1M |
| IPO Year | 1996 | 2001 |
| Metric | CDZIP | CGEN |
|---|---|---|
| Price | $21.76 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 4.8K | ★ 211.2K |
| Earning Date | N/A | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,313,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 69.79 | N/A |
| 52 Week Low | $18.80 | $1.37 |
| 52 Week High | $24.78 | $3.24 |
| Indicator | CDZIP | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 41.25 |
| Support Level | $21.65 | $2.34 |
| Resistance Level | $22.73 | $2.54 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 57.69 | 14.06 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, generating maximum revenue engaged in providing water filtration solutions for impaired or contaminated groundwater sources.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.